Study
 	Population	 	Treatment	 	Duration	 	SVR12 Rates
ION-1		GT 1 treatment-naïve
(including 15.7 percent
(136/865) with cirrhosis)
SOF/LDV	 	12 weeks	 	97.7% (209/214)
SOF/LDV + RBV	 	12 weeks	 	97.2% (211/217)
SOF/LDV	 	24 weeks	 	NA (n=217)
 	 	SOF/LDV + RBV	 	24 weeks	 	NA (n=217)
ION-2		GT 1 treatment-experienced
(including 20.0 percent
(88/440) with cirrhosis)
SOF/LDV	 	12 weeks	 	93.6% (102/109)
SOF/LDV+RBV	 	12 weeks	 	96.4% (107/111)
SOF/LDV	 	24 weeks	 	99.1% (108/109)
 	 	SOF/LDV+RBV	 	24 weeks	 	99.1% (110/111)
ION-3		GT 1 treatment-naïve		SOF/LDV	 	8 weeks	 	94.0% (202/215)
SOF/LDV + RBV	 	8 weeks	 	93.1% (201/216)
 	 	SOF/LDV	 	12 weeks	 	95.4% (206/216)
 
- See more at: http://www.gilead.com/news/press-releases/2013/12/gilead-announces-svr12-rates-from-three-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis-c-patients#sthash.J7azFZ1t.dpuf